<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4909">
  <stage>Registered</stage>
  <submitdate>15/10/2014</submitdate>
  <approvaldate>15/10/2014</approvaldate>
  <nctid>NCT02268786</nctid>
  <trial_identification>
    <studytitle>Single Embryo TrAnsfeR of Euploid Embryo</studytitle>
    <scientifictitle>Prospective, Multi-center, Randomized Controlled Trial Comparing Pregnancy Outcomes Following Selection and Single Embryo Transfer (SET) Based on Preimplantation Genetic Screening (PGS) by Next Generation Sequencing (NGS) Versus Standard Morphological Assessment</scientifictitle>
    <utrn />
    <trialacronym>STAR</trialacronym>
    <secondaryid>RGH-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infertility</healthcondition>
    <healthcondition>Aneuploidy</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Preimplantation Genetic Screening by NGS

Experimental: Group A - Intent to transfer single euploid embryo based on NGS testing (VeriSeq PGS) of biopsied blastocysts

No Intervention: Group B - Intent to transfer single embryo based on morphological assessment according to the Gardner scoring system (no PGS)


Other interventions: Preimplantation Genetic Screening by NGS
The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Ongoing Pregnancy - Rate of ongoing pregnancy at 20 weeks gestation between patients who received an embryo transfer in Groups A and and B.</outcome>
      <timepoint>Gestational Age of 20 Weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Fetal Aneuploidy Status - Fetal aneuploidy status by maternal cell-free DNA (cfDNA) testing using verifiÂ® prenatal test compared to PGS result and/or fetal karyotype if available.</outcome>
      <timepoint>Gestational Age of at least 10 Weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient undergoing IVF

          -  At least 2 blastocysts suitable for biopsy on day 5 or 6 of embryo development</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of more than two prior implantation failure following IVF

          -  History of more than one miscarriage of viable pregnancy

          -  One or both partners known to be carrier(s) of a chromosomal abnormality

          -  Known genetic carrier couple and/or one or both partners carrier of a known autosomal
             dominant disorder

          -  Any other non-study related preimplantation genetic testing

          -  Use of donor oocytes

          -  Use of gestational carrier (surrogate or donor egg recipient).

          -  Severe oligospermia (&lt;1,000,000 sperm/ml); Surgical Sperm Retrieval for reasons other
             than post-vasectomy and CAVD

          -  Low ovarian reserve with (FSH) &gt;10 IU/L on day 2-4 of a prior menstrual cycle and/or
             (AMH) &lt;7 pmol/L (or &lt;1 ng/ml)

          -  Gender selection cycles

          -  Concurrent participation in another clinical trial</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Screening</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Melbourne IVF - Melbourne</hospital>
    <postcode>3002 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxfordshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Illumina, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Reprogenetics (USA)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Genesis Genetics</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Reprogenetics (UK)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the current study is to evaluate the effect of preimplantation genetic
      screening (PGS) by next generation sequencing (NGS) compared to standard morphological
      assessment of embryos on pregnancy rates through a randomized controlled trial (RCT). All
      embryos will be vitrified and a single embryo transfer (SET) will be performed with either
      screened or unscreened embryos depending on randomization.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02268786</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Amy Mueller, MD</name>
      <address>Sponsor GmbH</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>